UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000028522
Receipt number R000032645
Scientific Title A clinical study for evaluating the safety of excessive consumption of corn germ extract (glucosylceramide fraction)
Date of disclosure of the study information 2017/08/03
Last modified on 2017/08/03 17:42:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A clinical study for evaluating the safety of excessive consumption of corn germ extract (glucosylceramide fraction)

Acronym

A clinical study for evaluating the safety of excessive consumption of corn germ extract

Scientific Title

A clinical study for evaluating the safety of excessive consumption of corn germ extract (glucosylceramide fraction)

Scientific Title:Acronym

A clinical study for evaluating the safety of excessive consumption of corn germ extract

Region

Japan


Condition

Condition

not for special condition

Classification by specialty

Medicine in general

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to evaluate the safety of overdose ceramide

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The number of the adverse event which have the causal relationship between the test food observed during test period

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

One capsule (10 mg of glucosylceramide ) a day

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >=

Gender

Male and Female

Key inclusion criteria

1)20<=age<=60
2)Male and female
3)Outpatients
4)Healthy adults
5)Those with normal blood test results (or evaluated by the primary investigator).
6)Those who are able to take the test food for a month
7)Those who keep daily lifestyle during the test period
8)Those who are able to consent by the document
9)Those who are not correspond to the exclusion criteria

Key exclusion criteria

1)Those who are with a history of treatment such as myocardial infarction or heart failure
2)Exclusion for diseases (atrial fibrillation, arrhythmia, liver failure, renal failure, cerebrovascular disease, arthritis, diabetes, dyslipidemia, those being treated with high blood pressure, and other chronic diseases, etc.)
3)Who are corresponding the criteria D of the scale of health screening Society
4)Those who take any drugs and supplements (including herbal medicine)
5)Those who are allergic (pharmaceuticals and test article-related food)
6)Those who are Pregnancy or lactation, or to be expected pregnant during the study period
7)Those who are participating in other clinical trials within a month
8)Those who has been determined to be inappropriate of the study

Target sample size

15


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Saori Fujisaki

Organization

NIPPON FLOUR MILLS CO.,LTD.

Division name

Innovation center

Zip code


Address

5-1-3 Midorigaoka, Atsugi, Kanagawa, Japan

TEL

046-222-6963

Email

s-fujisaki@nippn.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Mayumi Yamada

Organization

imeQ Co.Ltd.

Division name

DM

Zip code


Address

2-14-6 nishiwaseda shinjyu-city, Tokyo

TEL

03-6205-6222

Homepage URL


Email

m-yamada@imeq.co.jp


Sponsor or person

Institute

NIPPON FLOUR MILLS CO.,LTD.

Institute

Department

Personal name



Funding Source

Organization

NIPPON FLOUR MILLS CO.,LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団 札幌百合の会病院
SAPPORO YURINOKAI HOSPITAL


Other administrative information

Date of disclosure of the study information

2017 Year 08 Month 03 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2017 Year 03 Month 29 Day

Date of IRB


Anticipated trial start date

2017 Year 08 Month 08 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 08 Month 03 Day

Last modified on

2017 Year 08 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032645


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name